[Other] A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11汕-hydroxylase inhibitor, in Japanese patients with endogenous Cushing*s syndrome other than Cushing*s disease

magdy_shehab Post time Half hour(s) ago | Show all posts |Read mode
This post will be closed automatically in 2026-08-23 05:33
Reward10points

journalㄩEndocrine Journal

AuthorsㄩTomoaki Tanaka; Fumitoshi Satoh; Makoto Ujihara; Sanae Midorikawa; Tomomi Kaneko; Tamami Takeda; Akina Suzuki; Masahiko Sato; Akira Shimatsu

Published dateㄩ2020--

DOIㄩ10.1507/endocrj.ej19-0617

PDF linkㄩhttps://www.jstage.jst.go.jp/art ... 8/67_EJ19-0617/_pdf

Article linkㄩhttps://doi.org/10.1507/endocrj.ej19-0617

Article SourceㄩJapan Endocrine Society


Remarkㄩ

Best Answer

Please approve

View Full Content

Reply

Use magic Donate Report

All Reply1 Show all posts
Sweetums33 Post time Half hour(s) ago | Show all posts

This post has been completed

Completed attachments will be deleted within 24 hours.
Reply

Use magic Donate Report

Junior Member
  • post

  • reply

  • points

    40


Return to the list